ACECLOFENAC 100MG + PARACETAMOL 325MG + TRYPSIN-CHYMOTRYPSIN 150000 AU TABLET is a formulation based on a combination of Aceclofenac, Paracetamol, Trypsin, and Chymotrypsin. The formulation incorporates two conventional active pharmaceutical ingredients together with an enzyme combination specified based on enzyme activity. These characteristics generate specific formulation-development concerns with regard to the compatibility of ingredients, uniformity of blends, process conditions, and finished-product stability.
Aceclofenac is specified at 100MG, Paracetamol at 325MG, and the Trypsin-Chymotrypsin component at 150000 AU. The AU designation reflects an activity-based specification, requiring appropriate control of enzyme potency as part of raw-material qualification and finished-product testing.
Pharmaceutical excipients can be added as required to achieve the physical and manufacturing characteristics required of the finished formulation. These may include diluents, binders, disintegrants, glidants, lubricants, stabilizers, and other formulation aids.
Because enzyme components may possess different stability characteristics from conventional chemical ingredients, formulation development and subsequent formulation design may involve thorough evaluation of moisture, temperature, process stress, and excipient interactions. The finished formulation should produce a consistent distribution of each active component across the batch.
The specification of Trypsin and Chymotrypsin at an activity level of 150000 AU puts enzyme-related quality control testing at the forefront of this formulation. In contrast to conventional ingredients where quantity is primarily expressed as a mass-based specification, enzyme-containing ingredients may require activity-based testing to establish their functional quality.
During formulation development, the raw materials are evaluated based on their approved specifications. Characteristics such as identity, purity, particle properties, moisture content, and enzyme activity may be defined before manufacturing.
The active pharmaceutical ingredients Aceclofenac, Paracetamol, and the enzyme components may present contrasting powder morphologies and processing characteristics. Particle size, density, flowability, and moisture sensitivity can impact blend uniformity and resulting potency. Formulation scientists can assess these factors during preformulation development.
Premixing, blending, or other blending approaches may be utilized to achieve suitable uniformity of even lower-concentration components. Appropriate blending technique depends on the formulation and equipment used.
The compatibility of formulation ingredients can also influence product quality. The choice of excipients can be designed to produce optimal physical and chemical attributes of the final blend.
The manufacturing process may entail dispensing the authorized raw materials according to the approved manufacturing formula. The raw materials are weighed on suitable equipment and checked using approved testing procedures.
Depending on the properties of the powders and the formulation design, materials may require sieving, milling, premixing, or controlled blending before compression. Optimizing the sequence of component addition and blending speed is an important part of process development.
The enzyme component may be sensitive to processing conditions. Unnecessary exposure to elevated temperature or moisture should be avoided as far as possible.
Before proceeding to compression, the blended powder can be tested for parameters such as blend uniformity and moisture content. The compression parameters such as tablet weight and hardness can be determined during process development.
After compression, each batch can be tested for compliance with specified parameters such as weight, hardness, friability, visual appearance, and disintegration. The compression process should produce tablets with the desired physical properties.
Quality control and finished-product testing for the Aceclofenac, Paracetamol, and enzyme combination involves both conventional and specific enzyme-based testing. Conventional testing may assess appearance, weight variation, friability, disintegration, dissolution, impurity profile, and assay of the pharmaceutical ingredients.
The enzyme component testing, which is based on enzyme activity, is particularly important. Adequate validation and control of the enzyme activity in the finished product ensures consistent quality control.
Representative sample selection and control processes can support the monitoring of production batch uniformity. Validation of analytical procedures is essential to support reliable detection and quantification of ingredients and activities.
Managing the raw-materials and finished product through standardized dispensing, mixing, compression, packaging, and stability testing procedures ensures consistent quality control of the product.
Stability testing ensures that a drug substance or drug product conforms to identified specifications through its shelf life. For enzyme-containing formulations, activity testing can be an essential part of the stability assessment.
Other stability-related parameters may include appearance, assay, impurities, viscosity, dissolution, moisture content, hardness, and drug degradation. The package should provide an adequate barrier to moisture and light, and should be compatible with the ingredients.
Considerations for suitable packaging material include blister packs, strip packs, or bottles that can protect the formulation from environmental impacts. The sealing material can also protect the product against moisture ingress.
Stability data can be collected under specific conditions at predefined intervals. Such data can contribute to the validation of the packaging system and the determination of stability shelf life.
A stable product is supported by effective labeling with batch number, expiry date, storage conditions, and other regulatory information. The packaging system supports traceability and quality assurance over the product lifecycle.
Pharmaceutical companies can include ACECLOFENAC 100MG + PARACETAMOL 325MG + TRYPSIN-CHYMOTRYPSIN 150000 AU TABLET within a diverse portfolio of pharmaceutical formulations. Ensuring effective development, production, testing, and documentation of products supports the range of formulation strengths and designs.
The use of enzyme components, particularly with activity-based specifications, can impact quality control procedures. Ensuring consistency of enzyme activity across batches requires carefully controlled handling, testing, and documentation.
The organized development of a pharmaceutical product portfolio takes advantage of the requirements of formulation development, approval procedures, and process validation to deliver consistent quality. The pharma franchise opportunities also require comprehensive expertise in formulation design, control procedures, quality assurance, and supply chain management.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech